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Spencer B. King III, MD, MACC, Editor-in-Chief, JACC: Cardiovascular InterventionsN ow that the economy of China is in aperiod of readjustment, and the Shanghaistock market has undergone a dramatic
correction, one is tempted to think that everything
including interventional cardiology would be im-
pacted. It may be, but from my recent observations
that is hardly the case. While I was in China for the
Chinese Society of Cardiology meeting in Shanghai, I
visited several hospitals and laboratories in Beijing,
Shanghai, Wuhan, and Xi’an. What I observed was a
booming enterprise. Hospitals from middle-sized to
massive are performing 1,000 to 13,000 interventional
procedures per year. Laboratories are modern, and
some run almost 24/7. Teaching, or level-3 hospitals,
are the recipients of very large patient volumes with
some caring for 10,000 outpatient visits per day.
These are major urban centers, and I am sure rural
China is vastly different, but one is struck by the size
of these endeavors. The purpose of my extended visit
after the congress was to lecture and discuss clinical
research methods and preparation of manuscripts to
reﬂect the results. We talked about the principles of
novelty, accuracy, and relevance of manuscripts. As
usual, we stressed the preeminence of the planning
and design and execution of the project over the prep-
aration of the paper, but there were many questions
about the structure, the conﬂicts of interest, how
open to be about limitations, and what reviewers
respond to favorably. Among my many visits to China,
these discussions are becoming much more interac-
tive. Many investigators are highly experienced and
are becoming well published in leading interventional
journals. One young colleague posed the question as
to what interventional cardiology would be like in 5
years. I usually get these types of questions about
spans of 10 to 15 years, but in China, things are movingso fast that 5 years is a long time. I do not have to go
back to my ﬁrst visit to China 28 years ago, when
cath labs were hardly existent and bicycles were the
only transportation for doctors to get to the hospital,
to see the progress that has been made. Ten years
ago, there was very little research in China. During
this visit, I saw major contributions being made to
large sponsored trials, but more importantly, to
investigator-initiated studies to answer important
questions. For example, much remains to be learned
about antithrombotic therapy following percutaneous
coronary intervention (PCI). The balance between
controlling ischemic events and preventing excess
bleeding is a highly nuanced problem that Chinese
investigators have the capability to work out. One
size does not ﬁt all. Industry forges ahead with domes-
tic companies now dominating the stent market. I am
told that there is a growing interest in intellectual
property rights now that China is becoming an
innovator, not just an imitator. Various approaches
including abluminal bioabsorbable polymers, in-
creased endothelial cell–attracting luminal surfaces,
and different release kinetics are being pursued by
Chinese companies. I encountered interest in head-
to-head comparison to the most popular second-
generation stents. I encouraged these investigators
to pursue clinical endpoints primarily rather
than surrogate ones that have been used so exten-
sively in the past. There is pre-clinical research
ranging from valve bioengineering to genomic labs
studying myriad diseases from hypertrophic cardio-
myopathy to long-QT syndrome.
Five years for Chinese cardiology? I predict great
things for several reasons. On the clinical side, the
patient base is rapidly expanding (unfortunately). I
heard a set of statistics that suggests a higher per capita
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1912myocardial infarction rate in China than in the United
States, partly driven by the high smoking rate and
other environmental risks (massive urbanization and
air pollution). Cardiology training is moving at a rapid
pace with enthusiasm among young intervention-
alists, many of whom are women. On the research side,
I see increasing international collaboration with many
engaging in research abroad. In Xi’an, I sat with car-
diologists who had trained in Rotterdam, New York,
Philadelphia, Rochester, and Palo Alto. It is rewarding
discussing cases with colleagues. Chronic total occlu-
sion (CTO) carries a special fascination here as it does
elsewhere. A cadre of CTO operators recently con-
ducted a live-case conference in Xi’an. Colleagues
from Japan were invited, and tough cases were
attempted by teams from Japan and from China. I
found this type of collaboration very exciting, and the
competition was reported to have producedmany new
ideas for both groups. Some important questions that
might be pondered in China, as well as elsewhere, are:
 Which patients with stable coronary artery disease
are appropriate candidates for PCI?
 Can someone prove that opening CTO extends life?
 How far can society go in percutaneous valve
replacement, considering the magnitude of the
problem?
 What should be done about a growing population
of patients with advanced heart failure?
 Can the highly effective primary PCI programs in
the cities be exported to small communities or ru-
ral areas, or are other approached needed?
Investigators in China are becoming equipped to
address many of these issues, and we may all learn
from them.One ﬁnal lesson I learned while in China is that,
once again, noninvasive approaches are preferred.
The discussions went long in Wuhan, and the rush to
the airport to catch a ﬂight to Xi’an was tight. Trafﬁc
was favorable, however, and we reached the depar-
ture curb with enough time. After exiting the Buick
van (those seemed to be the standard limo), the
driver tried to open the rear door to retrieve our
luggage. Not only that door but all the doors
remained locked with the keys in the ignition, the
engine running, and our luggage still inside. A low-
level of panic began to set in. I thought that a solu-
tion would be soon forthcoming, but no one seemed
to have an answer. The trafﬁc police said there was
no one to open the car, and we should try a “surgical”
approach by breaking out a window. The driver
agreed, but the police refused to do it because sur-
veillance cameras would capture the event, and they
would be in serious trouble. Handing me a metal
baton, they suggested I do it. A Buick van window is
tougher than I thought, and the baton repeatedly
bounced off. Where was Tiger Woods’ former wife
with a ﬁve iron when we needed her? Finally, a man
on a motorcycle appeared and swiftly cannulated the
driver-side window and deftly directed the “guide-
wire” to release the door lock. Racing to the plane,
I once again realized the value of interventional
backup for failed surgical procedures. No randomized
controlled trial was needed.
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